[New basic preparations with prolonged action in the treatment of rheumatoid arthritis].
A long-term comparative study of the classic basic drug-d-Penicillamin and 2 new sulfa drugs: sulfasalazin and salazopyridazin used for the first time in rheumatology, was conducted. Both drugs were shown to produce a "basic" effect in rheumatoid arthritis and to exceed d-Penicillamin in their therapeutic action. Better results were obtained with salazopyridazin. The tolerance to the new antirheumatic sulfa drugs was quite satisfactory; no severe side-effects were noted. Both drugs extend the potentialities of antirheumatoid therapy of prolonged action and warrant further use and study.
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D008875:Middle Aged; D010396:Penicillamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011897:Random Allocation; D012460:Sulfasalazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; C009943:salazodin; D012460:Sulfasalazine; D010396:Penicillamine
Novye dlitel'no deĭstvuiushchie (bazisnye) preparaty v terapii revmatoidnogo artrita.